ijms-logo

Journal Browser

Journal Browser

Molecular Research of Cancer Metabolism and Biomarkers

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine, University Campus Bio-Medico of Rome, Rome, Italy
Interests: translational oncology; resistance to therapy; secretome signaling; microRNAs; cell transformation; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

It is well established that metabolic reprogramming is a major feature of neoplastic transformation and progression. Metabolic reprogramming involves complex pathway remodeling and multifaceted interactions between cancer cells and the TME, thereby influencing resistance to chemotherapy and biologicals, including immunotherapy. Despite this growing body of knowledge, the extent to which metabolic remodeling confers protumorigenic features in clinically relevant settings still needs to be elucidated and is critical for the development of metabolic modulators that can attenuate cancer progression in vivo. On the other hand, gaining knowledge about these processes goes hand in hand with the identification of prognostic and diagnostic biomarkers. These efforts clearly necessitate multidisciplinary approaches and a multifaceted omics approach.

We invite all colleagues to contribute to this interesting discussion led by Dr. Mario Cioce, who will be assisted by our Topical Advisory Panel Member Dr. Surbhi Chouhan (Department of Molecular Biology UT Southwestern Medical Center 5323 Harry Hines Blvd Dallas).

Dr. Mario Cioce
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic reprogramming
  • tumor microenvironment (TME)
  • resistance
  • metabolic modulator
  • multidisciplinary omics approach
  • cancer metabolism
  • biomarkers
  • cancer stem cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

25 pages, 11307 KiB  
Article
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma
by Ilaria Leoni, Giuseppe Galvani, Elisa Monti, Clara Vianello, Francesca Valenti, Luca Pincigher, Ambra A. Grolla, Marianna Moro, Camelia A. Coada, Alessandro Perrone, Valeria Righi, Sara Marinelli, Gloria Ravegnini, Catia Giovannini, Maurizio Baldassarre, Milena Pariali, Matteo Ravaioli, Matteo Cescon, Francesco Vasuri, Marco Domenicali, Massimo Negrini, Fabio Piscaglia, Romana Fato, Claudio Stefanelli, Laura Gramantieri, Christian Bergamini and Francesca Fornariadd Show full author list remove Hide full author list
Int. J. Mol. Sci. 2025, 26(8), 3808; https://doi.org/10.3390/ijms26083808 - 17 Apr 2025
Viewed by 180
Abstract
The approval of immunotherapy has revolutionized the management of hepatocellular carcinoma (HCC) patients. However, sorafenib remains a first-line therapeutic option for advanced patients and, in particular, for patients not eligible for immune checkpoint inhibitors, but its efficacy is limited by the onset of [...] Read more.
The approval of immunotherapy has revolutionized the management of hepatocellular carcinoma (HCC) patients. However, sorafenib remains a first-line therapeutic option for advanced patients and, in particular, for patients not eligible for immune checkpoint inhibitors, but its efficacy is limited by the onset of acquired resistance, highlighting the urgent need for predictive biomarkers. This study investigates the role of miR-22 in metabolic reprogramming and its potential as a biomarker in HCC. The analysis of miR-22 expression was performed in HCC patients and preclinical models by qPCR. Functional analyses in HCC cells evaluated GLUT1 as a direct miR-22 target. Cellular and metabolic assays evaluated the miR-22/GLUT1 axis’s role in metabolic changes, tumor aggressiveness, and sorafenib response. Circulating miR-22 was analyzed in sorafenib-treated HCC patients and rats. MiR-22 was downregulated in HCCs and associated with aggressive tumor features. Functionally, miR-22 modulated the HIF1A pathway, enhanced survival in stressful conditions, promoted a glycolytic shift, and enhanced cancer cell plasticity and sorafenib resistance via GLUT1 targeting. In addition, high serum miR-22 levels were associated with sorafenib resistance in HCC patients and rats. GLUT1 inhibition sensitized low miR-22-expressing HCC cells to sorafenib in preclinical models. These findings suggest that circulating miR-22 deserves attention as a predictive biomarker of sorafenib response. GLUT1 inhibition may represent a therapeutic strategy to combine with sorafenib, particularly in patients exhibiting high circulating miR-22 levels. Full article
(This article belongs to the Special Issue Molecular Research of Cancer Metabolism and Biomarkers)
Show Figures

Graphical abstract

Review

Jump to: Research

16 pages, 702 KiB  
Review
Glucose Metabolism and Tumor Microenvironment: Mechanistic Insights and Therapeutic Implications
by Wiktoria Andryszkiewicz, Julia Gąsiorowska, Maja Kübler, Karolina Kublińska, Agata Pałkiewicz, Adam Wiatkowski, Urszula Szwedowicz and Anna Choromańska
Int. J. Mol. Sci. 2025, 26(5), 1879; https://doi.org/10.3390/ijms26051879 - 22 Feb 2025
Viewed by 1049
Abstract
Metabolic reprogramming in cancer cells involves changes in glucose metabolism, glutamine utilization, and lipid production, as well as promoting increased cell proliferation, survival, and immune resistance by altering the tumor microenvironment. Our study analyzes metabolic reprogramming in neoplastically transformed cells, focusing on changes [...] Read more.
Metabolic reprogramming in cancer cells involves changes in glucose metabolism, glutamine utilization, and lipid production, as well as promoting increased cell proliferation, survival, and immune resistance by altering the tumor microenvironment. Our study analyzes metabolic reprogramming in neoplastically transformed cells, focusing on changes in glucose metabolism, glutaminolysis, and lipid synthesis. Moreover, we discuss the therapeutic potential of targeting cancer metabolism, focusing on key enzymes involved in glycolysis, the pentose phosphate pathway, and amino acid metabolism, including lactate dehydrogenase A, hexokinase, phosphofructokinase and others. The review also highlights challenges such as metabolic heterogeneity, adaptability, and the need for personalized therapies to overcome resistance and minimize adverse effects in cancer treatment. This review underscores the significance of comprehending metabolic reprogramming in cancer cells to engineer targeted therapies, personalize treatment methodologies, and surmount challenges, including metabolic plasticity and therapeutic resistance. Full article
(This article belongs to the Special Issue Molecular Research of Cancer Metabolism and Biomarkers)
Show Figures

Figure 1

Back to TopTop